Abstract
Freedom from viral contaminants is a paramount concern for recombinant biopharmaceuticals and plasma-derived medicinal products. Viral safety is achieved by a rigorous program of cell bank and source material testing in conjunction with a demonstration that product purification is capable of
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: PDA Journal of Pharmaceutical Science and Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
